Katherine Morel
9PUBLICATIONS
46CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Sep 02, 2025
EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.Beatriz German, Katherine L Morel, Teia Noel
|Aug 20, 2025
EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.Beatriz German, Katherine L Morel, Teia Noel
|Aug 08, 2024
MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.Beatriz German, Sarah A Alaiwi, Kun-Lin Ho
|Feb 14, 2024
MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer.Beatriz German, Jagpreet N Singh, Marcos AdS Fonseca
|Apr 26, 2021
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Katherine L Morel, Anjali V Sheahan, Deborah L Burkhart
|Apr 17, 2021
NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.Katherine L Morel, Anis A Hamid, John G Clohessy
Pageof 2
Frequent Collaborators
5 joint publications
Leigh Ellis
4 joint publications
David P Labbé
3 joint publications
Himisha Beltran
3 joint publications
Henry W Long
3 joint publications
Deborah L Burkhart
2 joint publications
Xintao Qui
2 joint publications
Beatriz German
2 joint publications
Simon R V Knott
2 joint publications
Christopher J Sweeney
2 joint publications
Matthew L Freedman
